David Gobel

Future vision applies, and the evidence shows Gobel co-founded and leads an organization with a concrete longevity goal, especially Methuselah Foundation's public target of making “90 the new 50 by 2030.” However, the provided evidence contains no direct personal vision statements, destination quotes, theory endorsements, or path/timeline/risk explanations from Gobel himself, so the score is moderate rather than high.

Primary citation metrics show very limited direct scientific publication impact: one OpenAlex-indexed work, h-index 1, i10-index 0, and 6 total citations. The available authored work is a 2025 Nature Aging meeting report on aging biomarkers rather than a field-shaping technical paper. Evidence suggests Gobel may have enabled longevity research through Methuselah Foundation, but the provided evidence does not document independently corroborated scientific outputs or specific enabled breakthroughs at a level that would justify a higher scientific-impact score.

The dimension applies because the evidence describes David Gobel as a co-founder and leader of Methuselah Foundation and CEO of Methuselah Fund, both longevity-focused capital-allocation institutions. However, the evidence provides no disclosed investment or donation amounts, no named transactions or grants, and no primary or independent corroboration of actual capital deployed. This supports some institution-building credit but not a high capital-deployed score.

The evidence supports a strong but not definitive strategic_taste score: Gobel appears to have made an early, thesis-coherent, high-risk institution-building bet by co-founding Methuselah Foundation in 2001 to advance healthy lifespan extension through prizes, research funding, project support, and venture incubation. The bet was plausibly contrarian given the supplied claim that healthy life extension was then viewed as foolish or dangerous. However, the record is thin, mostly self-published, and does not provide enough independent counterfactual detail or outcome attribution to justify a top-tier score.

David Gobel has credible field-creation evidence through co-founding and leading Methuselah Foundation, a longevity-focused biomedical nonprofit that funds research, ventures, projects, and prizes. The foundation's existence and Gobel's active role are independently corroborated by an academic source listing both Gobel and Methuselah Foundation in the longevity/biomarkers community, satisfying the independence gate for scoring above 5. However, most operational detail about the foundation's specific programs and impact comes from the foundation's own website, and the evidence provided does not independently document the scale or downstream field-wide effects of its prizes, grants, or SENS-related incubation.

The evidence supports some bravery/conviction through early, public commitment to longevity via co-founding Methuselah Foundation in 2001, when the foundation says such work was widely considered foolish and dangerous. However, the record provided is mostly self-published and does not document personal downside, major sacrifice, criticism endured, self-experimentation, or a bet sized relative to Gobel’s capacity, so the score should stay moderate-low with low confidence.

The dimension applies: Gobel is presented mainly as an institution-builder through Methuselah Foundation, with evidence of a real longevity platform connected to funding, prizes, grants, ventures, and field collaboration. That supports meaningful second-order leverage, but the supplied record gives little independently corroborated detail on scale, capital attracted, major follow-on projects, or measurable ecosystem effects, so the score should remain moderate rather than high.